BriaCell Therapeutics Corp. (BCTX) is priced at $7.27 after the most recent trading session. At the very opening of the session, the stock price was $7.71 and reached a high price of $7.71, prior to closing the session it reached the value of $7.30. The stock touched a low price of $7.25.Recently in News on September 9, 2021, BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants. BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that its board of directors (the “Board”) has authorized the Company’s repurchase program whereby the Company may purchase through the facilities of the TSX Venture Exchange (“TSXV”) or The NASDAQ Capital Market (“NASDAQ”) (i) up to 1,341,515 common shares (the “Common Shares”) and (ii) up to 411,962 publicly traded BCTXW warrants (the “Listed Warrants”) in total, representing 10% of the 13,415,154 Common Shares and 10% of the 4,119,622 Listed Warrants comprising the “public float” as of September 8, 2021, over the next 12 months (the “Buyback”). Independent Trading Group (ITG) Inc. will act as the Company’s advisor and dealer manager in respect of the Buyback. The Company expects to finalize the terms of the Buyback and formally commence the Buyback by September 14, 2021, subject to obtaining any necessary regulatory approvals. You can read further details here
BriaCell Therapeutics Corp. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $9.00 on 06/02/21, with the lowest value was $2.81 for the same time period, recorded on 04/20/21.
BriaCell Therapeutics Corp. (BCTX) full year performance was -3.18%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, BriaCell Therapeutics Corp. shares are logging -19.22% during the 52-week period from high price, and 158.26% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $2.81 and $9.00.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 958588 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the BriaCell Therapeutics Corp. (BCTX) recorded performance in the market was 75.06%, having the revenues showcasing 21.06% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 104.63M.
The Analysts eye on BriaCell Therapeutics Corp. (BCTX)
During the last month, 0 analysts gave the BriaCell Therapeutics Corp. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 5.05, with a change in the price was noted +3.96. In a similar fashion, BriaCell Therapeutics Corp. posted a movement of +120.83% for the period of last 100 days, recording 3,502,169 in trading volumes.
Technical rundown of BriaCell Therapeutics Corp. (BCTX)
Raw Stochastic average of BriaCell Therapeutics Corp. in the period of last 50 days is set at 70.43%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 63.14%. In the last 20 days, the company’s Stochastic %K was 68.26% and its Stochastic %D was recorded 71.66%.
Considering, the past performance of BriaCell Therapeutics Corp., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 75.06%. Additionally, trading for the stock in the period of the last six months notably improved by 89.61%, alongside a downfall of -3.18% for the period of the last 12 months. The shares increased approximately by 8.79% in the 7-day charts and went down by 21.67% in the period of the last 30 days. Common stock shares were driven by 21.06% during last recorded quarter.